This reporter (chinatimes.net.cn) reporter Yu Na in Beijing
Anhui Lerantang Pharmaceutical's Araliaceae capsules dropped from 2448 yuan to 68 yuan, a decrease of more than 97%; Inner Mongolia Lan The price reduction of compound licorice tablets produced by Tai Pharmaceutical Co., Ltd. is as high as 99.1%... A large number of drug price reduction information has been announced.
On September 16, the Sichuan Pharmaceutical Equipment Bidding and Purchasing Service Center announced the active price reduction information for 110 drugs, involving 64 pharmaceutical companies in the volume and price linkage areas, including Xinda, Kexing, Qilu, Zhengda Tianqing, Baiyunshan, Sinopharm Group, Simcere Pharmaceuticals, Yangtze River, China Resources Onde, Chengdu Better, Hunan Sailong, Shanghai Pharmaceutical Holdings, Xinlitai ( (Suzhou) and many other pharmaceutical companies are on the list of price cuts.
The price cut involves levofloxacin tablets, compound paracetamol tablets, nifedipine controlled release tablets, compound licorice tablets, bevacizumab injection, nivolumab Injection, Esomeprazole Sodium for Injection, Vitamin B12 Injection, Jinji Pills, Shugan Jieyu Capsules and many other varieties.
Medical strategy consultant Zhou Shu told the reporter of " China Times" that under the normalization of centralized procurement, the downward trend in drug prices is the general trend of the industry. The active price reduction of pharmaceutical companies is not only to comply with the market, but also to integrate online price supervision and credit evaluation. The result of the effect.
The price of medicines is not just "cut in the middle"
Lantai Pharmaceuticals is a comprehensive enterprise integrating the production and sales of salt, salt chemicals , medical and health products, etc.Compound licorice tablets are one of its representative products in the field of medicine and health. This time, Lantai Pharmaceuticals applied to directly reduce the linkage reference price of compound licorice tablets from 1200 yuan to 10.07 yuan. The price reduction is no longer "cut in half", but close to "cut in half."
In addition to compound licorice tablets, Lantai Pharmaceuticals also applied for a price reduction of compound bifendate tablets, and the price reduction rate also reached 97.2%.
Another surprising drop is Anhui Lerantang Pharmaceutical's Araliaceae Capsules (0.35g per capsule), which dropped directly from more than 1,000 yuan to tens of yuan. The instructions show that the main ingredients of the medicine are Aralia, Ganoderma lucidum, Red Ginseng, Schisandra, Wujiapi, rabbit silk, which is used for 's heart and spleen deficiency. Blood medicine, suitable for people including insomnia and neurasthenia, combined with chemical medicine to treat the root cause.
In addition, companies with higher price cuts include Renhe Yikang Group Co., Ltd., Harbin Medical University Pharmaceutical Co., Ltd., and Shanghai Pharmaceutical Kangdele (Shanghai) Pharmaceutical Co., Ltd., etc.
The linkage reference price of Daming Capsules (0.3g per capsule) of Harbin Medical University Pharmaceutical Co., Ltd. is 1,271.76 yuan. After the price reduction is applied for, the linkage reference price is 52.99 yuan, and the price reduction rate is 95.83%; Renheyikang Group Co., Ltd. Cinacalcet hydrochloride tablets (25mg (calculated as C22H22F3N)) linkage reference price is 198 yuan, after applying for price reduction, linkage reference price is 29.68 yuan, a decrease of 85%; Shanghai Pharmaceutical Kangdele (Shanghai) Pharmaceutical Co., Ltd.'s Rotigo The reference price of Ting patch (9mg/20cm2 (drug release 4mg/24h)) linkage is 1144.29 yuan, and the linkage reference price after applying for price reduction is 612 yuan, and the price reduction rate is 46.52%.
However, the prices of two anti-cancer drugs of Shanghai Pharmaceutical Holdings are almost unchanged, one is the anti-tumor drug nivolumab injection linkage, the reference price of which is reduced from 4587 to 4586.74, and dasatinib tablets from 7275 yuan Decreased to 7274.17.
Nivolumab injection is a fully human monoclonal antibody against PD-1 receptor ,The original research is American Bristol-Myers Squibb's , which is the first monoclonal antibody drug targeting PD-1 approved for registration in my country. Another Dasatinib tablet is used to treat the chronic phase, accelerated phase and blast phase (acute phase) of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) that is resistant to or intolerant to imatinib mesylate. Granule change and acute leaching change) adult patients.
Zhou Shu believes that in this price cut, the sharp drop in the price of proprietary Chinese medicines also shows from the side that the original price is ridiculously high. Guangdong is leading the joint 6 provinces to carry out the centralized procurement of Chinese patent medicines, involving a number of varieties with a sales volume of more than 100 million yuan. It can be foreseen that a large number of Chinese patent medicines will be reduced in price.
Online price regulation is becoming stricter
The proactive price cuts of pharmaceutical companies are behind the stricter supervision of online prices by provincial recruitment agencies.
On August 13, the Sichuan Pharmaceutical Equipment Bidding and Purchasing Service Center announced the "Sichuan Province Pharmaceutical Equipment Centralized Procurement and Pharmaceutical Price Monitoring Platform Online Drug Price Monitoring Regulations" (hereinafter referred to as the "Specifications"), where products are online on the Sichuan Provincial Platform , Its prices are included in the scope of drug price monitoring on the platform, including mass purchase of drugs, price linkage purchase of drugs, and record purchase of drugs.
According to the changes in drug prices on the platform, three intervals are divided into serious abnormal changes, abnormal changes and reasonable changes, and red, yellow, and green labels are implemented respectively to remind pharmaceutical companies and medical institutions to regulate price purchase behavior.
According to the "Specifications", the online product is the unit. Compared with the average purchase price of the same manufacturer, the same drug name, the same dosage form product, and the average purchase price in the past three years, the price increase is 50% (excluding 50%) Product prices within) are marked as green zone prices; product prices with a price increase of 50% (including 50%)-100% (excluding 100%) are marked as yellow zone prices; products with a price increase of more than 100%, Identified as the red zone price price. In addition, the monitoring results form a monthly report, which is reported to the Provincial Medical Security Bureau and the Provincial Commission for Discipline Inspection on a regular basis, and is sent to the medical institutions involved.
The industry believes that this means that once a drug company’s online product is marked as a red zone or even a yellow zone price, it is likely to be directly “passed” by medical institutions.
before July 2020,The "Implementation Plan for the Dynamic Adjustment of Pharmaceutical Sunshine Linking Network of the Shaanxi Provincial Public Resources Trading Center" stated that "If there is a new national minimum price for products in the price-limiting network catalog, the manufacturing company that linked the network must start from the date of implementation of the price. Report to the provincial platform within one month. If it is not declared in a timely or truthful manner, once verified, the qualification of the product to be linked to the Internet will be cancelled and recorded in the integrity file of the enterprise, and the product declaration will not be accepted within one year."
According to this, 7 companies including Chengdu Better, Kaifeng Connaught, Guangdong Zhongsheng, etc. have violated the above regulations and failed to declare the national minimum price as required by the 7 companies’ price-limited online products, resulting in the cancellation of online eligibility and credit for the company’s integrity file.
During the first round of "Inter-provincial Price Linkage" in Hunan Province this year, Guangzhou Baiyunshan Tianxin Pharmaceutical, Lukang Pharmaceutical Saite Company, Furen Pharmaceutical and other 13 pharmaceutical companies, because they have not According to the truthful reporting of the lowest online price information of other provinces, there was dishonesty behavior, and it was assessed as “general dishonesty” by the centralized pharmaceutical procurement platform of Hunan Province.
Source: China Times
Arrangement: Dai Wei Shen Jing
.-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-